Literature DB >> 15605189

Bacteriostatic and bactericidal activity of levofloxacin against clinical isolates from cystic fibrosis patients.

G Golini1, F Favari, F Marchetti, R Fontana.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15605189     DOI： 10.1007/s10096-004-1216-3

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  8 in total

1.  Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.

Authors:  M H Gotfried; L H Danziger; K A Rodvold
Journal:  Chest       Date:  2001-04       Impact factor: 9.410

2.  Bactericidal activity of levofloxacin and ciprofloxacin on clinical isolates of different phenotypes of Pseudomonas aeruginosa.

Authors:  B Segatore; D Setacci; M Perilli; N Franceschini; F Marchetti; G Amicosante
Journal:  Int J Antimicrob Agents       Date:  2000-01       Impact factor: 5.283

3.  Comparative bactericidal activity of fluoroquinolones against clinical isolates resistant to fluoroquinolones.

Authors:  L Drago; E De Vecchi; L Nicola; M Valli; F Marchetti; M R Gismondo
Journal:  J Chemother       Date:  2003-04       Impact factor: 1.714

Review 4.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

Review 5.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

Review 6.  Levofloxacin: an updated review of its use in the treatment of bacterial infections.

Authors:  Miriam Hurst; Harriet M Lamb; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Current and future perspectives for levofloxacin in severe Pseudomonas aeruginosa infections.

Authors:  F Marchetti; P Viale
Journal:  J Chemother       Date:  2003-08       Impact factor: 1.714

8.  Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa.

Authors:  B Segatore; D Setacci; M Perilli; N Franceschini; A De Santis; F Marchetti; G Amicosante
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191
  8 in total
  6 in total

1.  Dissecting novel virulent determinants in the Burkholderia cepacia complex.

Authors:  George P Tegos; Mark K Haynes; Herbert P Schweizer
Journal:  Virulence       Date:  2012-05-01       Impact factor: 5.882

Review 2.  Antibiotic resistance in Burkholderia species.

Authors:  Katherine A Rhodes; Herbert P Schweizer
Journal:  Drug Resist Updat       Date:  2016-07-30       Impact factor: 18.500

3.  Phenotypic and genotypic characterization of Pseudomonas aeruginosa from cystic fibrosis patients.

Authors:  I Leone; M G Chirillo; T Raso; M Zucca; D Savoia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-17       Impact factor: 3.267

4.  In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.

Authors:  Paula King; Olga Lomovskaya; David C Griffith; Jane L Burns; Michael N Dudley
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

5.  Efflux pump-mediated drug resistance in Burkholderia.

Authors:  Nicole L Podnecky; Katherine A Rhodes; Herbert P Schweizer
Journal:  Front Microbiol       Date:  2015-04-14       Impact factor: 5.640

6.  Outer membrane vesicles produced by Burkholderia cepacia cultured with subinhibitory concentrations of ceftazidime enhance pro-inflammatory responses.

Authors:  Se Yeon Kim; Mi Hyun Kim; Joo Hee Son; Seung Il Kim; Sung Ho Yun; Kyeongmin Kim; Shukho Kim; Minsang Shin; Je Chul Lee
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.